2E9.F Intervacc AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.0503 EUR
Close of Nov 11, 2026
0.0067 0.1118
Market cap
EUR 17.1M
P/E
-
P/B
0.84x
ROE
-35.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2E9.F undervalued?

Graham number

The Graham number of Intervacc AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Intervacc AB (publ) fundamental analysis

No fundamental analysis for Intervacc AB (publ) yet.

Intervacc AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Intervacc AB (publ)

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, wh…

Full company profile